1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Michael reaction acceptors (MRAs) are a class of active compounds. There is a great prospect to screen STAT3 inhibitors from Eupatorium lindleyanum, furthermore, to discover lead compounds for anti-triple-negative breast cancer (TNBC). In this study, glutathione (GSH) was employed, and a UPLC-MS screening method was developed to discover MRAs. We screened MRAs which can inhibit STAT3 using a STAT3-dependent reporter system. Six sesquiterpene lactones, including a new compound Eupalinolide O (1), together with five known compounds, Eupalinolide I (2), Eupalinolide K (3), Eupalinolide H (4), Eupalinolide J (5) and Eupalinolide G (6) were isolated. Eupalinolide J was identified as MRA that decreased luciferase activity of STAT3. Preliminary activity assessment showed that Eupalinolide J could inhibit the viability of TNBC cell lines. We demonstrated that Eupalinolide J, which is a natural typical MRA, has a notable inhibition of STAT3 activity and a potential cytotoxic activity against TNBC cell lines.

          Related collections

          Author and article information

          Journal
          Nat Prod Res
          Natural product research
          Informa UK Limited
          1478-6427
          1478-6419
          Feb 2019
          : 33
          : 4
          Affiliations
          [1 ] a College of Pharmaceutical Sciences , Zhejiang Chinese Medical University , Hangzhou , P. R. China.
          [2 ] b School of Medicine , Hangzhou Normal University , Hangzhou , P. R. China.
          [3 ] c Department of Pharmaceutics , Shaoxing Hospital of Traditional Chinese Medicine , Shaoxing , P. R. China.
          Article
          10.1080/14786419.2017.1396596
          29086600
          eb6823f0-f961-4fce-8cea-5a41e7cafd6e
          History

          STAT3 inhibitor,Sesquiterpene lactone,precise discovery,triple-negative breast cancer

          Comments

          Comment on this article